The Increasing Prevalence of Trigeminal Neuralgia Market Is Driving Market Growth

Trigeminal Neuralgia Market
Trigeminal Neuralgia Market

Trigeminal Neuralgia Treatment Market, by Treatment (Drug Type and Surgery), and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028.

Market Overview:

Trigeminal neuralgia is a medical condition, which causes acute facial pain, typically affecting one side of the face. The pain is often described as sharp, shooting, or electric shock-like and can be triggered by simple actions such as chewing, talking, or even touching the face. Anticonvulsants such as carbamazepine, oxcarbazepine, and gabapentin are often prescribed to reduce the pain associated with trigeminal neuralgia.

These medications work by reducing the sensitivity of the nerves that cause the pain. In cases where medication is not effective or the side effects are intolerable, surgery may be recommended. There are several surgical procedures available, including microvascular decompression, gamma knife radiosurgery, and balloon compression.

In some cases, a nerve block may be performed to temporarily relieve the pain. This involves injecting a local anesthetic into the affected nerve to block the pain signals. In addition to medication and surgery, lifestyle changes such as avoiding triggers (such as cold air, wind, or hot or cold drinks), reducing stress, and practicing relaxation techniques may help to reduce the frequency and severity of trigeminal neuralgia episodes.

Competitive Landscape:

Major players operating in the global Trigeminal Neuralgia Market include GlaxoSmithKline Plc., Novartis, Pfizer Inc., Trigemina Inc., Abbott Laboratories, Merz Pharma GmbH & Co., Biogen, Inc., Merz Pharma GmbH & Co., and Allergan Plc.

Key Market Drivers:

Increasing cases of trigeminal neuralgia in the world are expected to augment the growth of the global trigeminal neuralgia treatment market. For instance, according to John Wiley & Sons, Inc., the incidence rate of trigeminal neuralgia in the world is around 5.5 per 100,000 individuals every year.

Increasing technological developments related to trigeminal neuralgia are estimated to enhance the growth of the global Trigeminal Neuralgia Market.

Innovations and advancements in surgical procedures, minimally invasive techniques, and targeted drug therapies are fueling market growth by offering better treatment outcomes and improved patient experiences. Increasing awareness about trigeminal neuralgia and its available treatments among patients and healthcare professionals is driving the market growth.

Covid-19 Impact Analysis:

During the COVID-19 pandemic, the global Trigeminal Neuralgia Market witnessed several challenges. Transport restrictions and lockdown measures in several regions have also affected the market growth. On one hand, it led to the postponement of non-emergency surgical procedures, negatively impacting the market. On the other hand, it accelerated the adoption of telemedicine and remote consultations for the diagnosis and management of trigeminal neuralgia, which contributed to the market growth.

Key Takeaways:

· The North American market is expected to dominate the growth of the global trigeminal neuralgia treatment for market, driven by the high prevalence of the disease, advanced healthcare infrastructure, and the strong presence of key market players. For instance, according to the American Hospital Association, there are currently 6093 hospitals in the United States.

· The Asia-Pacific market is estimated to witness high growth in the global Trigeminal Neuralgia Market, attributed to the increasing prevalence of trigeminal neuralgia, improving healthcare infrastructure, and growing awareness about the condition. For instance, according to the Japan Hospital Association, there are currently 8.2 thousand hospitals in Japan.

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Bioresorbable Implants Can Also Help To Prevent Complications And Speed Up The Recovery Process

Image
Bioresorbable Implants Medical implants, either passive for structural support or for diagnosis and therapy with active electronics, are widely used in surgical applications. Although they have shown long-term biocompatibility, their removal imposes physical, biological and economical burdens on patients. To overcome this drawback, implantable devices exhibiting biodegradation in the body have been developed. These implants disappear inside the body after a certain time of use, and can be replaced with natural bone. The resorption of Bioresorbable Implants is driven by hydrolysis of the bonds linking their monomers. The amorphous portions of the polymer degrade first, while the crystalline regions remain intact and provide most of their mechanical strength. The monomers are then broken down into lactic and glycolic acids, which are converted to pyruvate and then processed through the citric acid cycle into water and carbon dioxide. The Bioresorbable Implants Market was valued at US$
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more